These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35239968)

  • 21. Ustekinumab as induction and maintenance therapy for ulcerative colitis - national extended follow-up and a review of the literature.
    Chetwood JD; Gupta S; Subramaniam K; De Cruz P; Moore G; An YK; Connor SJ; Kermeen M; Paramsothy S; Leong RW
    Expert Opin Drug Saf; 2024 Apr; 23(4):449-456. PubMed ID: 37909484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Data on Short-Term and Long-Term Treatment Results of Ustekinumab in Patients with Steroid-Resistant/Dependent Ulcerative Colitis.
    Komeda Y; Tribonias G; Kono M; Handa K; Omoto S; Takenaka M; Hagiwara S; Tsuji N; Nishida N; Kashida H; Kudo M
    Inflamm Intest Dis; 2023 Dec; 8(4):161-166. PubMed ID: 38115909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry.
    Chaparro M; Garre A; Iborra M; Sierra-Ausín M; Barreiro-de Acosta M; Fernández-Clotet A; de Castro L; Boscá-Watts M; Casanova MJ; López-García A; Lorente R; Rodríguez C; Carbajo AY; Arroyo MT; Gutiérrez A; Hinojosa J; Martínez-Pérez T; Villoria A; Bermejo F; Busquets D; Camps B; Cañete F; Manceñido N; Monfort D; Navarro-Llavat M; Pérez-Calle JL; Ramos L; Rivero M; Angueira T; Camo Monterde P; Carpio D; García-de-la-Filia I; González-Muñoza C; Hernández L; Huguet JM; Morales VJ; Sicilia B; Vega P; Vera I; Zabana Y; Nos P; Suárez Álvarez P; Calviño-Suárez C; Ricart E; Hernández V; Mínguez M; Márquez L; Hervías Cruz D; Rubio Iturria S; Barrio J; Gargallo-Puyuelo C; Francés R; Hinojosa E; Del Moral M; Calvet X; Algaba A; Aldeguer X; Guardiola J; Mañosa M; Pajares R; Piqueras M; García-Bosch O; López Serrano P; Castro B; Lucendo AJ; Montoro M; Castro Ortiz E; Mesonero F; García-Planella E; Fuentes DA; Bort I; Delgado-Guillena P; Arias L; Iglesias A; Calvo M; Esteve M; Domènech E; Gisbert JP
    J Crohns Colitis; 2021 Nov; 15(11):1846-1851. PubMed ID: 33860795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, Effectiveness, and Safety of Ustekinumab for the Treatment of Ulcerative Colitis: A Systematic Review.
    Gisbert JP; Parody-Rúa E; Chaparro M
    Inflamm Bowel Dis; 2024 Feb; 30(2):292-302. PubMed ID: 36715206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Dhaliwal J; McKay HE; Deslandres C; Debruyn J; Wine E; Wu A; Huynh H; Carman N; Crowley E; Church PC; Walters TD; Ricciuto A; Griffiths AM;
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1300-1308. PubMed ID: 33909911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.
    Hyams J; Damaraju L; Blank M; Johanns J; Guzzo C; Winter HS; Kugathasan S; Cohen S; Markowitz J; Escher JC; Veereman-Wauters G; Crandall W; Baldassano R; Griffiths A;
    Clin Gastroenterol Hepatol; 2012 Apr; 10(4):391-9.e1. PubMed ID: 22155755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis.
    Taxonera C; Olivares D; López-García ON; Alba C
    Aliment Pharmacol Ther; 2023 Mar; 57(6):610-619. PubMed ID: 36645145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
    Tursi A; Mocci G; Scaldaferri F; Napolitano D; Maresca R; Pugliese D; Semprucci G; Savarino E; Cuomo A; Donnarumma L; Bodini G; Pasta A; Maconi G; Cataletti G; Pranzo G; Rodinò S; Sebkova L; Costa F; Ferronato A; Gaiani F; Marzo M; Luppino I; Fabiano G; Paese P; Elisei W; Monterubbianesi R; Faggiani R; Grossi L; Serio M; Scarcelli A; Lorenzetti R; Allegretta L; Chiri S; Grasso G; Antonelli E; Bassotti G; Spagnuolo R; Luzza F; Fanigliulo L; Rocco G; Sacchi C; Zampaletta C; Rocchi C; Bolognini L; Bendia E; Bianco MA; Capone P; Meucci C; Colucci R; Tonti P; Neve V; Della Valle N; Felice C; Pica R; Cocco A; Forti G; Onidi FM; Usai Satta P; Checchin D; Gravina AG; Pellegrino R; Picchio M; Papa A
    Expert Opin Biol Ther; 2024; 24(1-2):101-109. PubMed ID: 38250818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
    Dayan JR; Dolinger M; Benkov K; Dunkin D; Jossen J; Lai J; Phan BL; Pittman N; Dubinsky MC
    J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):61-67. PubMed ID: 31058718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
    Sandborn WJ; Rutgeerts P; Gasink C; Jacobstein D; Zou B; Johanns J; Sands BE; Hanauer SB; Targan S; Ghosh S; de Villiers WJS; Colombel JF; Feagan BG
    Aliment Pharmacol Ther; 2018 Jul; 48(1):65-77. PubMed ID: 29797519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using Computer Vision to Improve Endoscopic Disease Quantification in Therapeutic Clinical Trials of Ulcerative Colitis.
    Stidham RW; Cai L; Cheng S; Rajaei F; Hiatt T; Wittrup E; Rice MD; Bishu S; Wehkamp J; Schultz W; Khan N; Stojmirovic A; Ghanem LR; Najarian K
    Gastroenterology; 2024 Jan; 166(1):155-167.e2. PubMed ID: 37832924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ustekinumab for treating ulcerative colitis: an expert opinion.
    Biancone L; Ardizzone S; Armuzzi A; Castiglione F; D'Incà R; Danese S; Daperno M; Gionchetti P; Rizzello F; Scribano ML; Vecchi M; Orlando A
    Expert Opin Biol Ther; 2020 Nov; 20(11):1321-1329. PubMed ID: 32662683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A critical review of ustekinumab for the treatment of active ulcerative colitis in adults.
    Vieujean S; Louis E; Danese S; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):413-430. PubMed ID: 36949608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3387-3396.e1. PubMed ID: 37391059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy.
    Chiappetta MF; Viola A; Mastronardi M; Turchini L; Carparelli S; Orlando A; Biscaglia G; Miranda A; Guida L; Costantino G; Scaldaferri F; Bossa F; Renna S; Cappello M; Alibrandi A; Orlando A; Armuzzi A; Fries W
    Expert Opin Biol Ther; 2021 Nov; 21(11):1483-1489. PubMed ID: 34521307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
    Iborra M; Ferreiro-Iglesias R; Maria Dolores MA; Mesonero Gismero F; Mínguez A; Porto-Silva S; García-Ramírez L; García de la Filia I; Aguas M; Nieto-García L; Suárez Ferrer C; Bastida G; Barreiro-De-Acosta M; Nos P
    Scand J Gastroenterol; 2024 Mar; 59(3):260-268. PubMed ID: 37933161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lasa JS; Olivera PA; Danese S; Peyrin-Biroulet L
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):161-170. PubMed ID: 34856198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies.
    Vermeire S; Feagan BG; Peyrin-Biroulet L; Oortwijn A; Faes M; de Haas A; Rogler G
    J Crohns Colitis; 2024 Jan; 18(1):54-64. PubMed ID: 37540206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.